- In Q1 2022, Khiron expects to surpass 1 million CAD in medical cannabis revenues in
the United Kingdom ("UK")
alone
- Total untapped potential for cannabis patients in the UK
exceeds 1M patients
- Supported by its clinic in the UK opened in late 2021, Khiron
has increased its sales volumes more than 240% in Q1 2022
compared to entire 2021
- Khiron's growing portfolio in the UK includes KHIRON 20/1, one
of the best-selling THC-predominant cannabis flower in the UK
market
TORONTO, May 10, 2022
/CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company")
(TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), the global medical
cannabis leader expanding throughout Europe and Latin
America, continues to demonstrate its market dominance in
the UK's medical cannabis industry with cannabis sales volume
growth of 240% in Q1 2022 compared to the entire 2021 year.
This growth is generated by Khiron's end-to-end solution of
government regulation, supply chain, distribution, and clinics
prescribing Khiron's medical cannabis products.
With a population of almost 67 million, the UK has a potential
of at least 1.5% medical cannabis patients1.
Khiron addresses the great potential in the UK with its medical
cannabis products and clinical services, which are increasingly
used by patients and medical practitioners. In late 2021, Khiron
opened its first European Zerenia™ Medical Cannabis Clinics in the
UK, offering telemedicine service to patients around the country,
and contributing to the Company's patient acquisition and retention
growth.
"Today, Khiron has already established market leadership in the
UK with it first two products on the market, and its KHIRON 20/1
THC-predominant strain is one of the best-selling medically
prescribed products in the UK market," comments Franziska
Katterbach, President of Khiron Europe. "In Q1 2022, we expect to
surpass our first 1 million
CAD in revenues in the UK, and as we expand our
portfolio, and increase our patient base, Khiron will consolidate
its market leadership within the country. In 2021, Europe accounted for 33% of Khiron's medical
cannabis revenues, at more than 1.5
million CAD. In Q1 2022 and beyond, Europe will represent over 50% of Khiron's
cannabis revenues, strengthening Khiron's position as a leader in
the global medical cannabis market."
(1) Management
estimates based on industry benchmarks
|
Khiron is headquartered in Toronto, with operations in Colombia, Germany, UK, Peru, and Brazil
About Khiron Life Sciences Corp.
Khiron is a leading
global medical cannabis company with core operations in
Latin America and Europe. Leveraging wholly-owned medical health
clinics and proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs, scientific
expertise, product innovation, and focus on creating access to
drive prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Germany, UK, Peru, and Brazil and is positioned to commence sales in
Mexico. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Notes
Forward-Looking
Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-achieves-united-kingdom-cannabis-sales-volume-growth-of-240-in-q1-2022-301543201.html
SOURCE Khiron Life Sciences Corp.